Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.

Raymond L. Comenzo,Efstathios Kastritis,Mathew S. Maurer,Jeffrey A. Zonder,Monique C. Minnema,Stefan Schönland,Ad Wechalekar,Giovanni Palladini,Xiang Qin,Sandra Y. Vasey,Imran Khan,Jordan Schecter,Giampaolo Merlini

Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.

2018

Raymond L. Comenzo
Efstathios Kastritis
Mathew S. Maurer
Jeffrey A. Zonder
Monique C. Minnema
Stefan Schönland
Ad Wechalekar
Giovanni Palladini
Xiang Qin
Sandra Y. Vasey
Imran Khan
Jordan Schecter
Giampaolo Merlini

8011Background: Systemic AL amyloidosis is characterized by disposition of insoluble amyloid fibrils into tissues and organs via clonal expansion of CD38+ plasma cells. The safety run-in of DARA SC...

Keywords:

Daratumumab
AL amyloidosis
Dexamethasone
Bortezomib
Dara
Amyloid
Pathology
Cancer research
Cyclophosphamide
Medicine
Immunoglobulin light chain
CD38

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations